
Prelude Therapeutics advances cancer drug trials, reports Q3 2026 loss of $12.5M with cash runway into Q2 2028
Prelude Therapeutics reported Q3 2026 financial results with a net loss of $12.5 million and $142.7 million in cash, funding operations into Q2 2028. The company is progressing clinical trials for PRT13722, a selective KAT6A degrader for HR+ breast c...



